Status:
COMPLETED
De-escalation - Antifungal Treatment Immunocompromised Patients
Lead Sponsor:
University Hospital, Lille
Conditions:
Invasive Fungal Disease
Critical Illness
Eligibility:
All Genders
18+ years
Brief Summary
A small proportion of intensive care unit patients receiving antifungals have a proven invasive fungal infection. However, antifungal treatment has side effects such as toxicity, emergence of resistan...
Detailed Description
This is a retrospective and prospective observational multicenter study, aiming to determine the incidence, and safety of antifungal de-escalation in immunocompromised patients, and also factors assoc...
Eligibility Criteria
Inclusion
- Adults immunocompromised patients hospitalized in intensive care units
- Predictable invasive mechanical ventilation duration \> 96h
- Signed consent (by patient or its representative)
- First antifungal treatment initiation in ICU for proven or suspected candida infection
Exclusion
- Pregnant or breast-feeding women.
- Fungal infection other than invasive candida
- Prophylactic antifungal treatment.
- Lack of informed consent
- Predictable mechanical ventilation duration less than 48 hours
- Patients discharged from ICU before the 5th day after initiation of TAF
Key Trial Info
Start Date :
January 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 7 2023
Estimated Enrollment :
275 Patients enrolled
Trial Details
Trial ID
NCT03774316
Start Date
January 28 2019
End Date
November 7 2023
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Lille
Lille, France, 59000